Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

CARLSBAD, Calif., July 23 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2009 Financial Results When: Thursday, August 6, 2009 at 8:30 a.m. ET / 5:30 a.m. PT ...

Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders

CARLSBAD, Calif., May 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals to provide a general corporate update in conjunction with the 2009 Annual Meeting of Stockholders. The co...

Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

NEW ORLEANS and CARLSBAD, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis' cardiovascular program review of development and late-stage research candidates, including presentations ...

FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

Isis to Host Conference Call Today at 8 a.m. EDT CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Genzyme Corp. (Nasdaq: GENZ ) announced today that the FDA has provided guidance regarding approval requirements for mip...

Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS

CARLSBAD, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to ISIS 333611 for the treatment of an inherited form of amyotrophic lateral sclerosis (ALS), commonly...

Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes

CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that...

Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012

- ISIS 301012 given generic name mipomersen sodium - Isis further reduces its 2007 net operating loss guidance to mid to high $20 million range - Isis will host a conference call this morning at 8:00 a.m. E.T. at http://www.isisph...

Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months

- Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study Have Been Dosed With ISIS 301012 for Approximately Five Months or More, and Four Have Been Dosed for More Than Six Months - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T. ...

Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis

CARLSBAD, Calif. and ABBOTT PARK, Ill., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Abbott (NYSE: ABT ) announced today that Abbott has completed its purchase of Ibis Biosciences, Inc., an Isis subsidiary, for a closing purchase price of $175 million. In ad...

Grassrootshealth Launches D*action Community Project to Solve Vitamin D Deficiency Crisis

Serving as a model for public health action on vitamin D, GrassrootsHealth, an advocacy organization has launched the D*action Community Project, a consortium of scientists, institutions and individuals committed to solving the worldwide vitamin D deficiency crisis and will hold its first event, ...

More>>

Isis in Medical Technology

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

Broad New Patent Granted CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that they have begun a phase 3 study of mipomersen in patients with heterozygo...

Genzyme and Isis Complete Licensing of Mipomersen

Conference call to be held today at 10 a.m. EDT CAMBRIDGE, Mass., and CARLSBAD, Calif., June 24 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license and collaboration agreement for mip...

Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012

- Results of animal studies distinguish liver effects of apoB inhibition from MTP inhibition and support liver safety of ISIS 301012 - Favorable changes in liver fat metabolism associated with apoB inhibition but not MTP inhibition - Results presented in an oral ses...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

- HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies Experienced 46% Further Reductions in LDL-C when Treated with 300 mg/week ISIS 301012 for 13 Weeks - Study Presented in Poster Session Today at DALM Symposium in New York ...

Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568

ISIS 325568 is an Antisense Drug Targeting Glucagon Receptor for Treatment of Type 2 Diabetes CARLSBAD, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today it has earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnso...

Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

*Isis Now Has Two Drugs From Its Metabolic Disease Program In Clinical Development CARLSBAD, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today it has initiated a Phase 1 study of ISIS 325568, an antisense drug de...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximally tolerated lipid-lowering therapies experienced 50% further reductions in LDL-C with similar reductions in other atherogenic when treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007 /PRNewswire-FirstCal...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

* ISIS 301012 coadministered with statins for only five weeks at 400 mg/week lowered LDL-C 47% beyond the levels achieved with statins alone, with similarly favorable effects on other atherogenic lipids NEW ORLEANS and CARLSBAD, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals...

OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

VANCOUVER and CARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced that preliminary data from ongoing clinical studies of OGX-011 will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO). Presenta...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its financial results for the quarter ended June 30, 2009. During 2009 isis has continued to successfully execute its business...

Isis in Biological News

CACI Awarded a Prime Position on $500 Million, Multiple-Award Program with Biometrics Operations and Support Services

...cquisition life cycle, and biometrics intelligence analysis services. This contract offers strategic value to the company as it is aligned with CACI's isis functional core competency across multiple customers in support of the warfighter, national defense, and homeland security. From equipping military o...

Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide

...ognized for its affordable price tag, the fi-5530C2 was selected for the "Editor's Choice" award because of its flexibility, provided by the TWAIN and isis drivers, its light weight, ledger-sized paper scanning, and superior software bundling including Kofax VRS Pro, Fujitsu ScandAll Pro, and Adobe Acroba...

Cold Spring Harbor Laboratory scientists devise potential approach to treat spinal muscular atrophy

...amage in growing nerve cells and the muscles they control. Now, in laboratory experiments, researchers at Cold Spring Harbor Laboratory (CSHL) and isis Pharmaceuticals have induced cells to replenish the protein by activating an existing, slightly modified copy of the mutant gene. These early results ...

Krill discovered living in the Antarctic abyss

... how they used a deep-diving, remotely operated vehicle (RoV ) known as the isis to film previously unknown behaviour of krill. Professor Andrew Clarke o...ined to the top 150 metres of the water column. The grant to purchase the isis RoV was led by Professor Paul A Tyler of NOCS. He says, Having the abili...

Harold Mooney and Peter Raven, winners of the BBVA Foundation Award for Conservation Biology

...wenty articles in Science and Nature. In addition, his research has been cited in over 12,000 scientific papers since 1988, earning him a place in the isis prestigious list of Highly Cited Researchers in Ecology and Environmental Sciences. Peter Raven has authored over 450 articles in scientific journals ...

Building blocks of life

... The 140 million construction of the isis Second Target Station at the Rutherford Appleton L...cond Target Station is an addition to the existing isis facility which supports an international community...of steel shielding along its 143m journey from the isis synchrotron to the target. With elements such as a...

Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis

...ading multi-national polymer synthesis company and isis Pharmaceuticals, Inc. (NASDAQ: ISIS), a leader in ...Through our strong collaborative relationship with isis Pharmaceuticals, we have had access to the very hi...t of our partnership with Nitto Denko Corporation, isis is pleased to incorporate NittoPhase?into its own ...

Isis in Biological Technology

Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences

CARLSBAD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Abbott's exercise of its option to purchase Ibis Biosciences, a subsidiary of Isis. Total acquisition price will be $2...

Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart failure When: Monday, December 1, 2...

Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call

CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals' business update When: Tuesday, July 1, 2008, at 10:00 a.m. ET / 7:00 a.m. PT Via internet: Simply log onto our ...

BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Isis To Receive $2 Million Milestone Payment CARLSBAD, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Bristol-Myers Squibb Company (NYSE: BMY ) has selected a compound from the companies' collaboration as a develo...

Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration

CAMBRIDGE, Mass. and CARLSBAD, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for their collaboration, which was ann...

Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen

Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that they have...

Webcast Alert: Isis Pharmaceuticals Announces its Analyst & Investor Day

CARLSBAD, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis' Analyst & Investor Day When: Tuesday, November 13, 2007, at 9:00 a.m. ET / 6:00 a.m. PT Where: http://www.isispharm.com How: ...

Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis

Total acquisition price will be $215 million Acquisition will expand Abbott's position in molecular diagnostics for infectious disease CARLSBAD, Calif. and ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Abbott (NYSE: ABT ) ...

OncoGenex Reports Second Quarter 2009 Financial Results

...ond-generation antisense technology, licensed from isis Pharmaceuticals (NASDAQ: isis ), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and isis partnered in the successful discovery of OGX-011, ...

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

...ond-generation antisense technology, licensed from isis Pharmaceuticals (NASDAQ: isis ), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and isis partnered in the successful discovery of OGX-011, ...

Isis in Biological Dictionary

Biopolymer

... is ... Isis") is an early stage, Rhode Island-based medical device company. ... MARKET :: TECHNOLOGY :: PRODUCT :: MANAGEMENT :: CONTACT :: © 2007 isis BIOPOLYMER ... treehugger > Science & Technology > biopolymer . Indoor Air Pollution. Organic Food ... We've had thermoformed biopoly...